

Susanne Vrtala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9216709/publications.pdf>

Version: 2024-02-01

154
papers

8,250
citations

31976

53
h-index

56724

83
g-index

157
all docs

157
docs citations

157
times ranked

3958
citing authors

#	ARTICLE	IF	CITATIONS
1	IgE recognition of the house dust mite allergen Der p 37 is associated with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1031-1043.	2.9	19
2	Response to González-Pérez et al. <i>Journal of Investigative Dermatology</i> , 2022, 142, 723-726.	0.7	1
3	Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3084-3095.	5.7	13
4	Der p 23-specific IgE response throughout childhood and its association with allergic disease: A birth cohort study. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	2.6	9
5	Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2177-2188.	5.7	31
6	IgE Epitopes of the House Dust Mite Allergen Der p 7 Are Mainly Discontinuous and Conformational. <i>Frontiers in Immunology</i> , 2021, 12, 687294.	4.8	13
7	The Molecular Allergen Recognition Profile in China as Basis for Allergen-Specific Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 719573.	4.8	11
8	Expression in <i>Escherichia coli</i> and Purification of Folded rDer p 20, the Arginine Kinase From <i>Dermatophagoides pteronyssinus</i> : A Possible Biomarker for Allergic Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 154.	2.9	14
9	Novel vaccines for allergen-specific immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 86-99.	2.3	12
10	Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1. <i>Frontiers in Immunology</i> , 2021, 12, 744544.	4.8	8
11	Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 958-967.e5.	2.9	11
12	Variation in IgE binding potencies of seven <i>Artemisia</i> species depending on content of major allergens. <i>Clinical and Translational Allergy</i> , 2020, 10, 50.	3.2	10
13	The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources. <i>World Allergy Organization Journal</i> , 2020, 13, 100118.	3.5	38
14	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2761-2768.e16.	3.8	8
15	Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1097-1108.	2.9	55
16	Microarray-Based Allergy Diagnosis: Quo Vadis?. <i>Frontiers in Immunology</i> , 2020, 11, 594978.	4.8	17
17	A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2461-2478.	5.7	32
18	Clinical and immunological differences between asymptomatic HDM-sensitized and HDM-allergic rhinitis patients. <i>Clinical and Experimental Allergy</i> , 2019, 49, 808-818.	2.9	24

#	ARTICLE	IF	CITATIONS
19	Selection of house dust mite-specific allergic patients by molecular diagnosis may enhance success of specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1248-1252.e12.	2.9	56
20	Dysregulated invertebrate tropomyosin-dectin-1 interaction confers susceptibility to allergic diseases. <i>Science Immunology</i> , 2018, 3, .	11.9	51
21	Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE cross-reactivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1653-1661.	5.7	23
22	Molecular allergen profiling in horses by microarray reveals Fag e 2 from buckwheat as a frequent sensitizer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1436-1446.	5.7	10
23	Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1425-1435.	5.7	15
24	House dust mites as potential carriers for IgE sensitization to bacterial antigens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 115-124.	5.7	48
25	Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1656-1659.e9.	2.9	36
26	Betamethasone prevents human rhinovirus- and cigarette smoke- induced loss of respiratory epithelial barrier function. <i>Scientific Reports</i> , 2018, 8, 9688.	3.3	19
27	Tropomyosins in mosquito and house dust mite cross-react at the humoral and cellular level. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1354-1363.	2.9	11
28	Molecular Aspects of Allergens and Allergy. <i>Advances in Immunology</i> , 2018, 138, 195-256.	2.2	81
29	Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: The EGEA study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 643-654.e6.	2.9	52
30	Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 301-303.e8.	2.9	21
31	Clinical validation of a house dust mite environmental challenge chamber model. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 266-268.e5.	2.9	13
32	Allergens, Diagnostics, and Therapeutic Aspects in House Dust Mite Allergy. , 2017, , 415-428.		0
33	Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance. <i>Seminars in Immunology</i> , 2017, 30, 67-80.	5.6	20
34	Identification by serological proteome analysis of paramyosin as prominent allergen in dust mite allergy. <i>Journal of Proteomics</i> , 2017, 166, 19-26.	2.4	8
35	International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. <i>World Allergy Organization Journal</i> , 2017, 10, 14.	3.5	80
36	Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 541-549.e8.	2.9	213

#	ARTICLE	IF	CITATIONS
37	The quantity and quality of $\hat{\pm}$ -gal-specific antibodies differ in individuals with and without delayed red meat allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 266-273.	5.7	38
38	Innate function of house dust mite allergens: robust enzymatic degradation of extracellular matrix at elevated pH. <i>World Allergy Organization Journal</i> , 2017, 10, 23.	3.5	5
39	Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. <i>PLoS ONE</i> , 2016, 11, e0160641.	2.5	30
40	Real-Life Study for the Diagnosis of House Dust Mite Allergy - The Value of Recombinant Allergen-Based IgE Serology. <i>International Archives of Allergy and Immunology</i> , 2016, 170, 132-137.	2.1	45
41	Wheat allergy in children evaluated with challenge and IgE antibodies to wheat components. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 119-125.	2.6	54
42	Prevention of allergic asthma through Der p 2 peptide vaccination. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 197-200.e1.	2.9	21
43	Mites and other indoor allergens " from exposure to sensitization and treatment. <i>Allergo Journal International</i> , 2015, 24, 68-80.	2.0	28
44	Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1083-1091.	2.9	108
45	Der p 11 Is a Major Allergen for House Dust Mite-Allergic Patients Suffering from Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 102-109.	0.7	93
46	Bekannte Allergene der Hausstaubmilbe: Struktur, Funktion und Relevanz. <i>Allergologie</i> , 2015, 38, 55-63.	0.1	3
47	Allergene der Hausstaubmilbe und Diagnostik der Hausstaubmilbenallergie. , 2015, , 303-313.		0
48	The high molecular weight glutenin subunit Bx7 allergen from wheat contains repetitive IgE epitopes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1316-1323.	5.7	23
49	Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. <i>Clinical and Experimental Allergy</i> , 2014, 44, 278-287.	2.9	32
50	Specific IgE reactivity to Tri a 36 in children with wheat food allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 585-587.	2.9	21
51	Advances in allergen-microarray technology for diagnosis and monitoring of allergy: The MeDALL allergen-chip. <i>Methods</i> , 2014, 66, 106-119.	3.8	210
52	Conversion of Der p 23, a New Major House Dust Mite Allergen, into a Hypoallergenic Vaccine. <i>Journal of Immunology</i> , 2014, 192, 4867-4875.	0.8	69
53	Recombinant house dust mite allergens. <i>Methods</i> , 2014, 66, 67-74.	3.8	44
54	Glutathione-S-Transferase: A Minor Allergen in Birch Pollen due to Limited Release from Hydrated Pollen. <i>PLoS ONE</i> , 2014, 9, e109075.	2.5	22

#	ARTICLE	IF	CITATIONS
55	Biochemical, Biophysical and IgE-Epitope Characterization of the Wheat Food Allergen, Tri a 37. <i>PLoS ONE</i> , 2014, 9, e111483.	2.5	24
56	Î±-Purothionin, a new wheat allergen associated with severe allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1000-1003.e4.	2.9	34
57	Allergen Content and in vivo Allergenic Activity of House Dust Mite Extracts. <i>International Archives of Allergy and Immunology</i> , 2013, 161, 287-288.	2.1	12
58	An assay that may predict the development of <sc>I</sc>g<sc>G</sc> enhancing allergenâ€specific <sc>I</sc>g<sc>E</sc> binding during birch immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1199-1202.	5.7	6
59	Identification of Der p 23, a Peritrophin-like Protein, as a New Major <i>Dermatophagoides pteronyssinus</i> Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets. <i>Journal of Immunology</i> , 2013, 190, 3059-3067.	0.8	177
60	The majority of allergenâ€specific IgE in the blood of allergic patients does not originate from bloodâ€derived B cells or plasma cells. <i>Clinical and Experimental Allergy</i> , 2012, 42, 1347-1355.	2.9	47
61	Molecular and Immunological Characterization of Tri a 36, a Low Molecular Weight Glutenin, as a Novel Major Wheat Food Allergen. <i>Journal of Immunology</i> , 2012, 189, 3018-3025.	0.8	49
62	Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 435-443.e4.	2.9	84
63	Varying Allergen Composition and Content Affects the in vivo Allergenic Activity of Commercial <i>Dermatophagoides pteronyssinus</i> Extracts. <i>International Archives of Allergy and Immunology</i> , 2012, 159, 253-262.	2.1	158
64	Molecular characterization of wheat allergens specifically recognized by patients suffering from wheatâ€induced respiratory allergy. <i>Clinical and Experimental Allergy</i> , 2012, 42, 597-609.	2.9	41
65	Carrierâ€bound nonallergenic <sc>D</sc>er p 2 peptides induce <sc>I</sc>g<sc>G</sc> antibodies blocking allergenâ€induced basophil activation in allergic patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 609-621.	5.7	39
66	Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. <i>Vaccine</i> , 2011, 29, 2140-2148.	3.8	29
67	Molecular characterization of Der p 10: a diagnostic marker for broad sensitization in house dust mite allergy. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1468-1477.	2.9	85
68	Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. <i>Molecular Immunology</i> , 2011, 48, 431-441.	2.2	33
69	Analysis of the Antibody Responses Induced by Subcutaneous Injection Immunotherapy with Birch and Fagales Pollen Extracts Adsorbed onto Aluminum Hydroxide. <i>International Archives of Allergy and Immunology</i> , 2010, 151, 17-27.	2.1	26
70	From Allergen Genes to Allergy Vaccines. <i>Annual Review of Immunology</i> , 2010, 28, 211-241.	21.8	202
71	Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-Î²1 and IL-10â€producing properties. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 638-645.e1.	2.9	122
72	Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1024-1031.e8.	2.9	40

#	ARTICLE	IF	CITATIONS
73	Nasal application of rBet v 1 or nonâ€“IgE-reactive T-cell epitopeâ€“containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1312-1315.e4.	2.9	20
74	Cigarette smoke facilitates allergen penetration across respiratory epithelium. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 398-405.	5.7	68
75	Review article: From allergen genes to new forms of allergy diagnosis and treatment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 299-309.	5.7	33
76	Characterization of Der p 21, a new important allergen derived from the gut of house dust mites*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 758-767.	5.7	84
77	Variability of IgE reactivity profiles among European mite allergic patients. <i>European Journal of Clinical Investigation</i> , 2008, 38, 959-965.	3.4	150
78	Nonâ€“IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 528-530.e1.	2.9	36
79	Mimotopes identify conformational B-cell epitopes on the two major house dust mite allergens Der p 1 and Der p 2. <i>Molecular Immunology</i> , 2008, 45, 1308-1317.	2.2	30
80	Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. <i>Molecular Immunology</i> , 2008, 45, 2486-2498.	2.2	53
81	Characterization of Folded Recombinant Der p 5, a Potential Diagnostic Marker Allergen for House Dust Mite Allergy. <i>International Archives of Allergy and Immunology</i> , 2008, 147, 101-109.	2.1	43
82	A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. <i>Biological Chemistry</i> , 2008, 389, 925-33.	2.5	29
83	Recombinant Allergens Promote Expression of Aminopeptidase-N (CD13) on Basophils in Allergic Patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 11-21.	2.1	23
84	Analysis of Epitope-Specific Immune Responses Induced by Vaccination with Structurally Folded and Unfolded Recombinant Bet v 1 Allergen Derivatives in Man. <i>Journal of Immunology</i> , 2007, 179, 5309-5316.	0.8	49
85	Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity. <i>Journal of Immunology</i> , 2007, 179, 1730-1739.	0.8	27
86	Exposure to a farming environment has allergen-specific protective effects on TH2-dependent isotype switching in response to common inhalants. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 351-358.	2.9	71
87	Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. <i>Clinical and Experimental Allergy</i> , 2007, 37, 1277-1285.	2.9	94
88	Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 734-741.	2.9	37
89	The role of Foxp3+ T cells in longâ€“term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 173-180.	5.7	41
90	Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. <i>Clinical and Experimental Allergy</i> , 2006, 36, 32-39.	2.9	55

#	ARTICLE	IF	CITATIONS
91	Allergen-induced interleukin-9 production <i>in vitro</i> : correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13. <i>Clinical and Experimental Allergy</i> , 2006, 36, 174-182.	2.9	44
92	Allergen cleavage by effector cell-derived proteases regulates allergic inflammation. <i>FASEB Journal</i> , 2006, 20, 967-969.	0.5	25
93	Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils. <i>Blood</i> , 2006, 108, 1365-1365.	1.4	1
94	Development of an <i>in vitro</i> system for the study of allergens and allergen-specific immunoglobulin E and immunoglobulin G: Fcε receptor I supercross-linking is a possible new mechanism of immunoglobulin G-dependent enhancement of type I allergic reactions. <i>Clinical and Experimental Allergy</i> , 2005, 35, 774-781.	2.9	21
95	Comparison of purified <i>Dermatophagoides pteronyssinus</i> allergens and extract by two-dimensional immunoblotting and quantitative immunoglobulin E inhibitions. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1384-1391.	2.9	41
96	Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. <i>Clinical and Experimental Allergy</i> , 2004, 34, 115-122.	2.9	38
97	Component-resolved diagnosis of house dust mite allergy with purified natural and recombinant mite allergens. <i>Clinical and Experimental Allergy</i> , 2004, 34, 597-603.	2.9	156
98	Immunotherapy of Allergic Disease. <i>Advances in Immunology</i> , 2004, 82, 105-153.	2.2	71
99	Strategies for converting allergens into hypoallergenic vaccine candidates. <i>Methods</i> , 2004, 32, 313-320.	3.8	43
100	Vaccination with genetically engineered allergens prevents progression of allergic disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14677-14682.	7.1	340
101	Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch pollen allergen. <i>European Journal of Immunology</i> , 2003, 33, 1667-1676.	2.9	51
102	Analysis of the sensitization profile towards allergens in central Africa. <i>Clinical and Experimental Allergy</i> , 2003, 33, 22-27.	2.9	99
103	A major IgE epitope-containing grass pollen allergen domain from Phl p 5 folds as a four-helix bundle. <i>Protein Engineering, Design and Selection</i> , 2002, 15, 635-642.	2.1	19
104	Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. <i>Immunology</i> , 2002, 107, 523-529.	4.4	40
105	Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2002, 32, 1448-1453.	2.9	37
106	Release of allergen-bearing cytoplasm from hydrated pollen: A mechanism common to a variety of grass (Poaceae) species revealed by electron microscopy. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 108, 109-115.	2.9	96
107	Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice. <i>International Archives of Allergy and Immunology</i> , 2001, 126, 68-77.	2.1	55
108	Induction of Blocking Antibodies with T Cell Epitope-Containing Hypoallergenic Recombinant Bet v 1 Fragments. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 107-108.	2.1	0

#	ARTICLE	IF	CITATIONS
109	Mucosal Tolerance Induction with Hypoallergenic Molecules in a Murine Model of Allergic Asthma. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 391-394.	2.1	22
110	A Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5, Defined by a Human Monoclonal IgE Antibody. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 80-84.	2.1	0
111	Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. <i>FASEB Journal</i> , 2001, 15, 2045-2047.	0.5	115
112	Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild type by skin prick and intradermal testing: results obtained in a French population. <i>Clinical and Experimental Allergy</i> , 2000, 30, 1076-1084.	2.9	78
113	T Cell Epitope-Containing Hypoallergenic Recombinant Fragments of the Major Birch Pollen Allergen, Bet v 1, Induce Blocking Antibodies. <i>Journal of Immunology</i> , 2000, 165, 6653-6659.	0.8	110
114	A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain. <i>Journal of Immunology</i> , 2000, 165, 3849-3859.	0.8	77
115	Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. <i>FEBS Letters</i> , 2000, 465, 39-46.	2.8	56
116	Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: A study performed with purified recombinant pollen allergens. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 803-813.	2.9	47
117	Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 101-109.	2.9	47
118	Expulsion of allergen-containing materials from hydrated rye grass (<i>Lolium perenne</i>) pollen revealed by using immunogold field emission scanning and transmission electron microscopy. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 1140-1145.	2.9	68
119	Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. <i>FASEB Journal</i> , 1999, 13, 843-856.	0.5	105
120	Clinical Evaluation of Genetically Engineered Hypoallergenic rBet v 1 Derivatives. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 216-217.	2.1	9
121	An immunoglobulin-like fold in a major plant allergen: the solution structure of Phl p 2 from timothy grass pollen. <i>Structure</i> , 1999, 7, 943-952.	3.3	46
122	Genetically Engineered and Synthetic Allergen Derivatives: Candidates for Vaccination against Type I Allergy. <i>Biological Chemistry</i> , 1999, 380, 815-24.	2.5	63
123	Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 218-219.	2.1	32
124	pET-prof, a plasmid for high-level expression of recombinant peptides fused to a birch profilin-derived hexadecapeptide tag: A system for the detection and presentation of recombinant antigens. <i>Gene</i> , 1999, 237, 333-342.	2.2	2
125	The Importance of Recombinant Allergens for Diagnosis and Therapy of IgE-Mediated Allergies. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 171-176.	2.1	22
126	Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 969-977.	2.9	85

#	ARTICLE	IF	CITATIONS
127	Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (<i>Phleum pratense</i>) pollen. <i>Journal of Immunology</i> , 1999, 163, 5489-96.	0.8	58
128	Recombinant allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 552-561.	5.7	105
129	The Immunoglobulin E-Allergen Interaction: A Target for Therapy of Type I Allergic Diseases. <i>International Archives of Allergy and Immunology</i> , 1998, 116, 167-176.	2.1	28
130	Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. <i>Journal of Immunology</i> , 1998, 160, 6137-44.	0.8	74
131	Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. <i>Journal of Immunology</i> , 1998, 161, 7031-9.	0.8	53
132	Division of the Major Birch Pollen Allergen, Bet v 1, into Two Non-Anaphylactic Fragments. <i>International Archives of Allergy and Immunology</i> , 1997, 113, 246-248.	2.1	19
133	Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.. <i>Journal of Clinical Investigation</i> , 1997, 99, 1673-1681.	8.2	186
134	Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: Different allergenicity of Bet v 1 and Bet v 2. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 98, 913-921.	2.9	37
135	Immunologic characterization of purified recombinant timothy grass pollen (<i>Phleum pratense</i>) allergens (Phl p 1, Phl p 2, Phl p 5)1. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 781-787.	2.9	99
136	High-Level Expression in <i>Escherichia coli</i> and Purification of Recombinant Plant Profilins: Comparison of IgE-Binding Capacity and Allergenic Activity. <i>Biochemical and Biophysical Research Communications</i> , 1996, 226, 42-50.	2.1	20
137	Recombinant Allergens. <i>Advances in Experimental Medicine and Biology</i> , 1996, , 185-196.	1.6	8
138	Profilin: A Novel Pan-Allergen and Actin-Binding Protein in Plants. , 1996, , 269-278.		2
139	Humoral Immune Responses to Recombinant Tree Pollen Allergens (<i>Bet v </i> and <i>Bet v) Tj ETQq1 1 0.784314 rgBT /Ov and Immunology, 1995, 107, 290-294.	2.1	22
140	Recombinant Allergens: Basic Aspects and New Therapeutic Concepts. , 1995, , 167-182.		1
141	IgE-binding capacity of recombinant timothy grass (<i>Phleum pratense</i>) pollen allergens. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 94, 88-94.	2.9	61
142	Complementary DNA cloning of the major allergen Phl p I from timothy grass (<i>Phleum pratense</i>); recombinant Phl p I inhibits IgE binding to group I allergens from eight different grass species. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 94, 689-698.	2.9	119
143	cDNA Cloning and Expression of Timothy Grass (<i>Phleum pratense</i>) Pollen Profilin in <i>Escherichia coli</i> : Comparison with Birch Pollen Profilin. <i>Biochemical and Biophysical Research Communications</i> , 1994, 199, 106-118.	2.1	78
144	Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction.. <i>Journal of Biological Chemistry</i> , 1994, 269, 28323-28328.	3.4	74

#	ARTICLE	IF	CITATIONS
145	Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. <i>Journal of Biological Chemistry</i> , 1994, 269, 28323-8.	3.4	62
146	Molecular characterization of Phl pII, a major timothy grass (<i>Phleum pratense</i>) pollen allergen. <i>FEBS Letters</i> , 1993, 335, 299-304.	2.8	80
147	Properties of Tree and Grass Pollen Allergens: Reinvestigation of the Linkage between Solubility and Allergenicity. <i>International Archives of Allergy and Immunology</i> , 1993, 102, 160-169.	2.1	130
148	Monitoring of two allergens, Bet v I and profilin, in dry and rehydrated birch pollen by immunogold electron microscopy and immunoblotting. <i>Journal of Histochemistry and Cytochemistry</i> , 1993, 41, 745-750.	2.5	56
149	Identification of profilin as an actin-binding protein in higher plants. <i>Journal of Biological Chemistry</i> , 1993, 268, 22777-22781.	3.4	102
150	cDNA cloning of a major allergen from timothy grass (<i>Phleum pratense</i>) pollen; characterization of the recombinant Phl pV allergen. <i>Journal of Immunology</i> , 1993, 151, 4773-81.	0.8	102
151	Identification of profilin as an actin-binding protein in higher plants. <i>Journal of Biological Chemistry</i> , 1993, 268, 22777-81.	3.4	90
152	Diagnosis of Grass Pollen Allergy with Recombinant Timothy Grass <i>Phleum pratense</i> Pollen Allergens. <i>International Archives of Allergy and Immunology</i> , 1992, 97, 287-294.	2.1	133
153	Profilin, a Novel Plant Pan-Allergen. <i>International Archives of Allergy and Immunology</i> , 1992, 99, 271-273.	2.1	46
154	Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. <i>Journal of Allergy and Clinical Immunology</i> , 1991, 88, 889-894.	2.9	156